Published in Health Business Week, May 14th, 2004
This SciClone sponsored study is designed to build on both the immunomodulator effects of Zadaxin and the potent anti-viral capabilities of nucleoside analog drugs such as lamivudine. SciClone holds a granted U.S. patent for the treatment of hepatitis B using Zadaxin in combination with lamivudine that does not expire until 2018.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.